LBRX LBRX Bipolar Depression Programs — Direct Research And Development Expenses

Similar metrics at other companies

GERNResearch and clinical expenses — R&D

$13M-5.1%

TYRAOther Development Programs — Research And Development Expense

$849K+65.2%

WVEHD Programs — Research And Development Expense

$63K-94.6%

AMLXOther Programs — Research And Development Expense Excluding Acquired In Process Cost

$7.98M+111%

ARQTOther program costs — R&D

$95K-92.0%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

Questions, answered.

What is LBRX's bipolar depression programs — direct research and development expenses?

LBRX (LBRX) reported bipolar depression programs — direct research and development expenses of $3.01M in Q1 2026.

What does bipolar depression programs — direct research and development expenses mean?

This metric represents the total direct costs incurred specifically for research and development activities related to clinical programs targeting bipolar depression. It captures expenditures such as clinical trial costs, regulatory filing fees, and specialized laboratory testing dedicated to advancing these specific neuropsychiatric therapeutic candidates. Monitoring this spend provides insight into the company's capital allocation strategy and the pace of development for its bipolar depression pipeline.